Interaction between pre-treatment drug use and heterogeneity of psychiatric diagnosis predicts outcomes in outpatients with co-occurring disorders

Oladunni Oluwoye; Katherine Hirchak; Emily Leickly; Jordan Skalisky; Sterling McPherson; Debra Srebnik; John M Roll; Richard K Ries; Michael G McDonell

doi:10.1016/j.psychres.2017.11.070

Interaction between pre-treatment drug use and heterogeneity of psychiatric diagnosis predicts outcomes in outpatients with co-occurring disorders

Psychiatry Res. 2018 Feb:260:233-235. doi: 10.1016/j.psychres.2017.11.070. Epub 2017 Nov 29.

Authors

Oladunni Oluwoye¹, Katherine Hirchak², Emily Leickly³, Jordan Skalisky⁴, Sterling McPherson⁵, Debra Srebnik⁶, John M Roll⁷, Richard K Ries⁸, Michael G McDonell⁹

Affiliations

¹ Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: oladunni.oluwoye@wsu.edu.
² Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: katherine.hirchak@wsu.edu.
³ Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: emily.leickly@wsu.edu.
⁴ Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: jordan.skalisky@wsu.edu.
⁵ Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA; Providence Medical Research Center, Providence Health Care, Spokane, WA, USA. Electronic address: smcpherson05@wsu.edu.
⁶ Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: Debra.Srebnik@kingcounty.gov.
⁷ Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: johnroll@wsu.edu.
⁸ Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: rries@u.washington.edu.
⁹ Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, WA, USA; Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA; Program of Excellence in Addictions Research, Washington State University, Spokane, WA, USA. Electronic address: mmcdonell@wsu.edu.

Abstract

We examined whether the interaction of baseline stimulant use, assessed by urine drug tests, and type of serious mental illness (SMI) diagnosis predicted stimulant use in a trial of contingency management (CM). The interaction between baseline stimulant use and SMI diagnoses was significant in the overall sample (p=0.002) when controlling for the main effects of treatment condition, baseline stimulant use, and SMI diagnosis. Similar results were also found within the CM sample. Individuals with bipolar disorder were more or less likely, depending on their baseline stimulant-drug test results, to use stimulants during treatment compared to those with other SMI diagnoses.

Keywords: Contingency management; Serious mental illness; Stimulant use.

Publication types

Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Adult
Behavior Therapy / methods*
Bipolar Disorder / epidemiology
Bipolar Disorder / therapy*
Central Nervous System Stimulants* / urine
Comorbidity
Depressive Disorder, Major / epidemiology
Depressive Disorder, Major / therapy*
Female
Humans
Male
Middle Aged
Outcome Assessment, Health Care*
Schizophrenia / epidemiology
Schizophrenia / therapy*
Substance-Related Disorders / epidemiology
Substance-Related Disorders / therapy*

Substances

Central Nervous System Stimulants

Abstract

Publication types

MeSH terms

Substances

Grants and funding